Higher-order epistasis drives evolutionary unpredictability toward novel antibiotic resistance

Read the full article See related articles

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

The rapid evolution of extended-spectrum β-lactamases (ESBLs) represents a global health threat, undermining the efficacy of β-lactams, the most extensively used antibiotic class. To elucidate the evolutionary dynamics underlying β-lactam resistance, we constructed a comprehensive combinatorial mutant library comprising all 55,296 possible TEM-1 β-lactamase variants integrating 18 clinically observed mutations across 13 key residues. Over eight million empirical fitness measurements were obtained under selection pressure with both a native antibiotic substrate (ampicillin) and a novel antibiotic (aztreonam), establishing the largest experimentally determined fitness landscape for antibiotic resistance to date. Through graph-theoretic and epistatic analyses, we discovered that selection with ampicillin resulted in weak epistasis, with mutants rarely surpassing the fitness of the wild-type enzyme. Conversely, aztreonam selection elicited extensive higher-order epistasis, generating a rugged fitness landscape characterized by increased phenotypic unpredictability. Interpretable machine-learning analyses identified context-dependent epistatic interactions necessary for achieving high-level aztreonam resistance. Further evolutionary statistical analyses, including direct coupling analysis and latent generative landscapes, showed that top-performing TEM-1 variants consistently adhered to conserved epistatic patterns found in naturally occurring β-lactamases. Our findings demonstrate that higher-order epistasis critically shapes fitness landscape ruggedness when enzymes adapt to novel substrates, whereas adaptations to native substrates exhibit predictably smoother landscapes. This integrated experimental and computational framework provides a foundation for predictive evolutionary pharmacology, enabling assessments of newly developed β-lactams or emerging β-lactamase variants for their potential contribution to ESBL evolution. Importantly, incorporating graph-theoretically informed evolutionary constraints can strategically disrupt evolutionary pathways, presenting a viable approach to mitigate the rise of antibiotic resistance.

Article activity feed